Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.

Karin B. Ø. Dieperink

Status: Completed

Conditions: Multiple Myeloma

Treatments: Drug: Bortezomib

Study type: Observational

Funder types: Other

Identifiers

NCT05163405

Velcade at home

Details and patient eligibility

About

In the present study, we have trained 10 patients in subcutaneous self-administration of Velcade. After their training, patients will alternately receive their treatment in the hospital and at home by self-administration. In keeping with common practice, a nurse contacts the patients by telephone before 9.00 am on the day of treatment to ensure that the patient is physically "fit" to receive the medication and to discuss any side effects. To highlight the advantages and disadvantages of the changed treatment practice from the perspectives of both patients and healthcare professionals, data is collected from two consecutive semi-structured interviews with n = 10 patients and n = 1 focus group interview of the healthcare professionals involved. Moreover, time registration of medication administration both at the hospital and in the patients' home is done. The qualitative data will be analyzed via the method of condensation and continual quantitative data will form the basis of a cost-benefit analysis.

Enrollment: 10 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Patients must have Multiple Myeloma
• Patients (or their relatives) must be deemed physically and cognitively suitable and willing for self-administration of subcutaneous Velcade
• Patients must be able to understand and speak Danish
• Patients must have received a minimum of 1 treatment cycle in the outpatient clinic

Exclusion criteria

• Lack of willingness to participate in scheduled interviews
• Patients who are cognitively affected
• Must not be receiving trial treatment